Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2018 Filed Feb 5, 2018 23:31 UTC |
Ricks David ADirector · President & CEO
|
GiftCommon Stock | 11,764 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000072 · wf-form4_151787345344416.xml · nonDerivative · entry 3 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,486 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:31 UTC |
Ricks David ADirector · President & CEO
|
Tax withholdingCommon Stock | 9,559 | $81.45 | $778,580.55 |
DisclosureSEC source: 0000059478-18-000072 · wf-form4_151787345344416.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:31 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionCommon Stock | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000072 · wf-form4_151787345344416.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:33 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
Exercise / conversionRestricted Stock Unit · Derivative | 15,993 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000074 · wf-form4_151787358167346.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,993 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:33 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
Tax withholdingCommon Stock | 7,133 | $81.45 | $580,982.85 |
DisclosureSEC source: 0000059478-18-000074 · wf-form4_151787358167346.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,224 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:33 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
Exercise / conversionCommon Stock | 15,993 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000074 · wf-form4_151787358167346.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:37 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · derivative · entry 5 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:37 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Tax withholdingCommon Stock | 9,294 | $81.45 | $756,996.30 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,826 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:37 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionCommon Stock | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Sep 24, 2018 20:45 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,596 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000236 · wf-form4_153782188376663.xml · derivative · entry 7 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by spouse Disclosed balance after: 0 Underlying: Common Stock · 9,596 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 01, 2018 Filed Sep 24, 2018 20:45 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
Tax withholdingCommon Stock | 4,280 | $81.45 | $348,606.00 |
DisclosureSEC source: 0000059478-18-000236 · wf-form4_153782188376663.xml · nonDerivative · entry 3 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by spouse Disclosed balance after: 75,954 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| February 01, 2018 Filed Sep 24, 2018 20:45 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
Exercise / conversionCommon Stock | 9,596 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000236 · wf-form4_153782188376663.xml · nonDerivative · entry 2 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by spouse Disclosed balance after: 80,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:55 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantRestricted Stock Unit · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000030 · wf-form4_151743932243299.xml · derivative · entry 3 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:55 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 3,759 | $87.60 | $329,288.40 |
DisclosureSEC source: 0000059478-18-000030 · wf-form4_151743932243299.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,709 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:57 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000033 · wf-form4_151743942666014.xml · derivative · entry 3 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:57 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantCommon Stock | 22,890 | $87.60 | $2,005,164.00 |
DisclosureSEC source: 0000059478-18-000033 · wf-form4_151743942666014.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,043 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:57 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
GrantRestricted Stock Unit · Derivative | 12,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000034 · wf-form4_151743944753235.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,222 Underlying: Common Stock · 12,222 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 22:57 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
GrantCommon Stock | 12,437 | $87.60 | $1,089,481.20 |
DisclosureSEC source: 0000059478-18-000034 · wf-form4_151743944753235.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,654 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:00 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 8,889 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000037 · wf-form4_151743959511817.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,889 Underlying: Common Stock · 8,889 shares Expires 2019-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:00 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 9,937 | $87.60 | $870,481.20 |
DisclosureSEC source: 0000059478-18-000037 · wf-form4_151743959511817.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,760 F1 · balance_after: Since the date of the reporting person's last ownership report, he transferred 2,111 shares of common stock to his ex-wife pursuant to a domestic relations order. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:00 UTC |
Ricks David ADirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 12,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000038 · wf-form4_151743964008872.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,222 Underlying: Common Stock · 12,222 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:00 UTC |
Ricks David ADirector · President & CEO
|
GrantCommon Stock | 12,407 | $87.60 | $1,086,853.20 |
DisclosureSEC source: 0000059478-18-000038 · wf-form4_151743964008872.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,483 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:04 UTC |
Shah Aarti S.SVP & CIO
|
GrantCommon Stock | 2,868 | $87.60 | $251,236.80 |
DisclosureSEC source: 0000059478-18-000040 · wf-form4_151743985024452.xml · nonDerivative · entry 1 Shah Aarti S. · CIK 0001725292 · SVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,709 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:06 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000042 · wf-form4_151743996649400.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,111 Underlying: Common Stock · 11,111 shares Expires 2019-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:06 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 1,363 | $87.60 | $119,398.80 |
DisclosureSEC source: 0000059478-18-000042 · wf-form4_151743996649400.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 14,872 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:06 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 12,412 | $87.60 | $1,087,291.20 |
DisclosureSEC source: 0000059478-18-000042 · wf-form4_151743996649400.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,436 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:07 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GrantRestricted Stock Unit · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000044 · wf-form4_151744001846526.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,111 Underlying: Common Stock · 11,111 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:07 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GrantCommon Stock | 12,662 | $87.60 | $1,109,191.20 |
DisclosureSEC source: 0000059478-18-000044 · wf-form4_151744001846526.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,794 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:08 UTC |
Norton JohnaSenior VP, Global Quality
|
GrantCommon Stock | 1,599 | $87.60 | $140,072.40 |
DisclosureSEC source: 0000059478-18-000046 · wf-form4_151744008557820.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,092 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:10 UTC |
Smiley Joshua LSVP and CFO
|
GrantCommon Stock | 7,202 | $87.60 | $630,895.20 |
DisclosureSEC source: 0000059478-18-000049 · wf-form4_151744021514077.xml · nonDerivative · entry 1 Smiley Joshua L · CIK 0001725189 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,029 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:11 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 5,491 | $87.60 | $481,011.60 |
DisclosureSEC source: 0000059478-18-000050 · wf-form4_151744025255646.xml · nonDerivative · entry 1 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,053 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:13 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 1,933 | $87.60 | $169,330.80 |
DisclosureSEC source: 0000059478-18-000053 · wf-form4_151744037789017.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,030 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:13 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantRestricted Stock Unit · Derivative | 12,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000054 · wf-form4_151744039642749.xml · derivative · entry 3 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,778 Underlying: Common Stock · 12,778 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:13 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantCommon Stock | 16,158 | $87.60 | $1,415,440.80 |
DisclosureSEC source: 0000059478-18-000054 · wf-form4_151744039642749.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,214 Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:15 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantRestricted Stock Unit · Derivative | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000056 · wf-form4_151744053419039.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,722 Underlying: Common Stock · 9,722 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:15 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantCommon Stock | 9,316 | $87.60 | $816,081.60 |
DisclosureSEC source: 0000059478-18-000056 · wf-form4_151744053419039.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,364 Read SEC document |
| January 29, 2018 Filed Feb 5, 2018 23:27 UTC Amendment |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 1,365 | $87.60 | $119,574.00 |
DisclosureSEC source: 0000059478-18-000070 · wf-form4a_151787325808208.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 14,874 F1 · shares: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F1 · balance_after: This amendment is being filed to correctly report the amount disposed in column 4, and to correct the number of securities beneficially owned following the reported transaction, as reported in column 5. F2 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 29, 2018 Filed Sep 24, 2018 20:45 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 4,279 | $87.60 | $374,840.40 |
DisclosureSEC source: 0000059478-18-000236 · wf-form4_153782188376663.xml · nonDerivative · entry 1 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by spouse Disclosed balance after: 70,638 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 16, 2018 Filed Jan 30, 2018 21:15 UTC Amendment |
Alvarez RalphDirector
|
GrantCommon Stock | 128 | $85.29 | $10,917.12 |
DisclosureSEC source: 0000059478-18-000022 · wf-form4a_151734691081795.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,630 F1 · date: Amended to correct the transaction date of the originally filed Form 4. Read SEC document |
| January 16, 2018 Filed Jan 30, 2018 21:19 UTC Amendment |
Fyrwald J ErikDirector
|
GrantCommon Stock | 64 | $85.29 | $5,458.56 |
DisclosureSEC source: 0000059478-18-000024 · wf-form4a_151734715775454.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,159 Read SEC document |
| January 16, 2018 Filed Jan 30, 2018 21:23 UTC Amendment |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 113 | $85.29 | $9,637.77 |
DisclosureSEC source: 0000059478-18-000026 · wf-form4a_151734740498961.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,426 F1 · date: Amended to correct the transaction date of the originally filed Form 4. Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 21:09 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 128 | $85.29 | $10,917.12 |
DisclosureSEC source: 0000059478-18-000008 · wf-form4_151622334123851.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,630 Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 21:13 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 64 | $85.29 | $5,458.56 |
DisclosureSEC source: 0000059478-18-000010 · wf-form4_151622361809620.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,159 Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 21:19 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 113 | $85.29 | $9,637.77 |
DisclosureSEC source: 0000059478-18-000012 · wf-form4_151622397706861.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,426 Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 20:20 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 127 | $86.08 | $10,932.16 |
DisclosureSEC source: 0000059478-17-000257 · wf-form4_151380124434505.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,502 Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 20:26 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 112 | $86.08 | $9,640.96 |
DisclosureSEC source: 0000059478-17-000259 · wf-form4_151380157685568.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,313 Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 16:26 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 8,300 | $88.89 | $737,753.80 |
DisclosureSEC source: 0001209191-17-065573 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,075,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.76 to $88.99, inclusive. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 16:26 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 191,700 | $88.17 | $16,901,422.20 |
DisclosureSEC source: 0001209191-17-065573 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,084,104 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.75 to $88.745, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 20:01 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
SaleCommon Stock | 12,500 | $86.46 | $1,080,750.00 |
DisclosureSEC source: 0000059478-17-000249 · wf-form4_151319528674708.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,522 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $86.09 to $86.65. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 20:05 UTC |
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
|
GrantRestricted Stock Unit · Derivative | 34,615 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000251 · wf-form4_151319550696770.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · SVP&Pres, LillyDiab & LillyUSA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,615 Underlying: Common Stock · 34,615 shares Expires 2021-12-11 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.